医学
奥马佐单抗
中止
加药
危险系数
回顾性队列研究
内科学
比例危险模型
置信区间
免疫学
免疫球蛋白E
抗体
作者
Ditte Georgina Zhang,Mia‐Louise Nielsen,Jennifer Astrup Sørensen,Somaia Naassan,Christian Vestergaard,Emek Kocatürk,Zarqa Ali,Jacob P. Thyssen,Alexander Egeberg,Simon Francis Thomsen
摘要
A considerable proportion of patients with CSU require modifications to the recommended omalizumab dosing regimen. A positive BHRA was the strongest predictor for dose escalation, while male sex and fast treatment response were the strongest predictors for dose reduction. Our study highlights the need for individualized strategies in managing CSU.
科研通智能强力驱动
Strongly Powered by AbleSci AI